|Day Low/High||83.12 / 83.81|
|52 Wk Low/High||69.35 / 89.72|
Consolidation, improving equity prices and sufficient firepower for deals continue to fuel med tech M&A, according to EY's Jeff Greene.
Identifying this week's bullish and bearish reversal patterns.
State-backed Chinese pharmaceutical companies have shown interest.
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT) concerning possible violations of federal securities laws.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT).
Levi & Korsinsky announces it has commenced an investigation of Medtronic plc ("Medtronic" or the "Company") (NYSE:MDT) concerning possible violations of federal securities laws.
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT) investors concerning the Company and its officers' possible violations of...
Medtronic is still working to fill back orders.
The Trump administration's creep towards scrapping certain tax regulations could revive inversion deals that have allowed U.S. companies to avoid billions of dollars in taxes.
A deal could happen.
Drones to the rescue!
Integra announced in February its intent to acquire Codman Neurosurgery from Johnson & Johnson.
Though IBM continues to face major revenue headwinds, its software and services expertise in numerous fields makes it a valuable ally to tech giants and others.
U.S. stock futures rise Thursday but European shares fluctuate after global oil prices turn sharply lower.
U.S. oil producers are becoming more important in any calculation about oil prices.
Prepare for a week of Fedspeak as members prime markets for a potential interest rate hike in June.
Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.
First serious down day in ages? Jim Cramer says it's as normal as rain; and he has an umbrella for you.
The firm gave the company an $87 price target.
Medtronic, J&J and Cardinal Health appear poised to benefit from an aging U.S. population, say investment experts.
From Abbott Labs to Wynn, these names rate checking out.
It's a wonder to me how split this market really is.
Consider how paltry the number of stocks making new highs has been.
The Cordis and Medtronic acquisitions are meant to shield Cardinal from the pricing swings of drug distribution.